Literature DB >> 8506520

Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy.

J Esquivel1, J Vidal-Jove, M A Steves, P H Sugarbaker.   

Abstract

BACKGROUND: Peritoneal carcinomatosis has been regarded as a uniformly lethal clinical entity. Recently, dose-intensive treatments combining cytoreductive surgery and intraperitoneal chemotherapy have resulted in long-term survival in selected patients.
METHODS: This article reports the morbidity and mortality associated with this new treatment strategy in 45 consecutive treatments of 43 patients with peritoneal carcinomatosis treated during an 18-month interval.
RESULTS: The duration of median postoperative ileus was 21 days, and increased age of the patient and extent of cytoreduction caused an increased incidence of ileus. Twenty-one complications occurred in 17 patients (37.7%). Complications related to enteric function included fistula (n = 4), bile leak (n = 1), pancreatitis (n = 1), and anastomotic disruption (n = 1). There were two early and two late episodes of postoperative bleeding requiring reoperation. Six patients had pneumonia and one had deep vein thrombosis. There were no deaths. Six of the seven complications related to enteric function occurred in patients who had undergone induction intraperitoneal chemotherapy before cytoreductive surgery plus early postoperative intraperitoneal chemotherapy.
CONCLUSIONS: As a result of these findings, induction intraperitoneal chemotherapy is only recommended for patients with low-volume intraabdominal cancer. In most patients surgical removal of peritoneal carcinomatosis before intraperitoneal chemotherapy is recommended. Because of the significant morbidity related to treatment of peritoneal carcinomatosis, careful patient selection and favorable long-term results of treatment are required.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506520

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

1.  Catheterization-associated complications of intraperitoneal chemotherapy in advanced gastric cancer.

Authors:  Meng Ye; Hong-Ming Pan; Hai-Yun Wang; Fang Lou; Wei Jin; Yu Zheng; Jin-Ming Wu
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

Review 2.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 3.  [Morbidity and mortality of hyperthermic intraperitoneal chemoperfusion].

Authors:  J O W Pelz; C-T Germer
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

4.  Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Methodology, Drugs and Bidirectional Chemotherapy.

Authors:  S J Valle; N A Alzahrani; W Liauw; P H Sugarbaker; A Bhatt; D L Morris
Journal:  Indian J Surg Oncol       Date:  2016-02-05

5.  Hyperthermic intraperitoneal chemoperfusion (HIPEC) decrease wound strength of colonic anastomosis in a rat model.

Authors:  J O W Pelz; J Doerfer; M Decker; A Dimmler; W Hohenberger; T Meyer
Journal:  Int J Colorectal Dis       Date:  2007-01-24       Impact factor: 2.571

6.  S-1 and the treatment of gastric cancer with peritoneal dissemination.

Authors:  Kunihiko Izuishi; Reiji Haba; Yoshio Kushida; Kyuichi Kadota; Ryusuke Takebayashi; Takanori Sano; Hisashi Usuki; Mohammad Akram Hossain; Hirohito Mori; Tsutomu Masaki; Yasuyuki Suzuki
Journal:  Exp Ther Med       Date:  2011-06-20       Impact factor: 2.447

7.  [Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy].

Authors:  G Glockzin; N Ghali; S A Lang; A Agha; H J Schlitt; P Piso
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

8.  Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.

Authors:  C F Verschraegen; S Kumagai; R Davidson; B Feig; P Mansfield; S J Lee; D S Maclean; W Hu; A R Khokhar; Z H Siddik
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-29       Impact factor: 4.553

Review 9.  Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer.

Authors:  P H Sugarbaker
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.